Miwa, Hiroto
Igarashi, Ataru
Teng, Lida
Uda, Akihito
Deguchi, Hisato
Tango, Toshiro
Funding for this research was provided by:
Takeda Pharmaceutical Company Ltd.
Article History
Received: 22 November 2018
Accepted: 14 March 2019
First Online: 27 March 2019
Compliance with ethical standards
:
: Hiroto Miwa has received research funding from Takeda Pharmaceutical Company, Ltd., Otsuka Pharmaceutical Company, Ltd., Daiichi Sankyo Company, Ltd., and Eisai Co., Ltd., and honorarium from Takeda Pharmaceutical Company, Ltd., Otsuka Pharmaceutical Company, Ltd., Daiichi Sankyo Company, Ltd., Eisai Co., Ltd., and AstraZeneca K. K.; Ataru Igarashi has received research grants from Pfizer Japan Inc., CSL Behring Japan Inc., Gilead Science K. K., and Fuji Film K. K., consulting fees from Novartis Pharma K. K., AbbVie GK, Milliman, Sony Inc., and Eli Lilly Japan K. K., and lecture fees from Chugai Pharmaceutical Company, Ltd., CRECON Research and Consulting Inc., Terumo Corporation, Bristol-Myers Squibb K. K., and Creativ-Ceutical K. K.; Toshiro Tango has received consulting fees from Takeda Pharmaceutical Company, Ltd., AbbVie GK, Ajinomoto Pharma, and Lion Corporation; Akihito Uda and Hisato Deguchi are employees of Takeda Pharmaceutical Company, Ltd.; Lida Teng has no conflict of interest.